Micillo M, Salerno M, Officioso A, Perna E, Gasparini N, Pisaturo L, Di Maio S
Department of Pediatrics, University Federico II, Naples, Italy.
J Pediatr Endocrinol Metab. 2000 Jul;13 Suppl 1:787-90. doi: 10.1515/jpem.2000.13.s1.787.
The impact of treatment of central precocious puberty (CPP) with gonadotropin-releasing hormone agonists (GnRHa) on final height remains controversial. We analyzed the long term results of 23 girls with CPP treated with triptorelin or leuprolide. Their "near final height" (NFH) assessed at a bone age of at least 14 years and expressed as SDS, was compared either with predicted height before treatment (PAH) or with parental height (TH). We also compared NFH of 12 girls treated before 8 years of age (7.0 +/- 0.5 yr) with NFH of 11 girls treated after 8 years old (8.5 +/- 0.3 yr). The NFH of the 23 girls (-0.9 +/- 1.0 SDS) was not different either from PAH (-0.85 +/- 1.5 SDS) or from TH (-0.5 +/0.6 SDS). Earlier treated girls reached a NFH (-0.97 +/- 1.0 SDS) not different from later treated girls (-0.91 +/- 1.0 SDS; p = ns) and both groups reached parental height (NFH - TH = -0.44 +/- 1 and -0.09 +/- 0.83 SDS, respectively). In conclusion, our patients, treated either earlier or later, reached a near final height comparable to predicted height and familial target; however, these results might still improve further because the girls have not yet reached their final adult height.
促性腺激素释放激素激动剂（GnRHa）治疗中枢性性早熟（CPP）对最终身高的影响仍存在争议。我们分析了23例接受曲普瑞林或亮丙瑞林治疗的CPP女童的长期结果。将她们在骨龄至少为14岁时评估的“接近最终身高”（NFH）以标准差积分（SDS）表示，与治疗前预测身高（PAH）或父母身高（TH）进行比较。我们还比较了12例8岁前（7.0±0.5岁）接受治疗的女童与11例8岁后（8.5±0.3岁）接受治疗的女童的NFH。23例女童的NFH（-0.9±1.0 SDS）与PAH（-0.85±1.5 SDS）或TH（-0.5±0.6 SDS）无差异。早期治疗的女童达到的NFH（-0.97±1.0 SDS）与晚期治疗的女童（-0.91±1.0 SDS；p=无显著性差异）无差异，两组均达到父母身高（NFH-TH分别为-0.44±1和-0.09±0.83 SDS）。总之，我们的患者无论治疗早晚，其接近最终身高与预测身高和家族目标相当；然而，由于女童尚未达到最终成人身高，这些结果可能仍会进一步改善。
